Scancell Holdings (SCLP)


Latest News

Result of AGM

RNS Number: 3096T Scancell Holdings Plc 11 October 2017 11 October 2017 Scancell Holdings Plc ("Scancell" or the "Company") Results of AGM Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting were duly passed. For Further Information: Dr ...

Directorate Change

RNS Number: 1039T Scancell Holdings Plc 10 October 2017 10 October 2017 Scancell Holdings Plc ("Scancell" or the "Company") Scancell appoints Dr Cliff Holloway as Chief Executive Officer Experienced life sciences executive with in-depth oncology expertise Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatmen...

Notice of AGM

RNS Number: 6869Q Scancell Holdings Plc 14 September 2017 14 September 2017 Scancell Holdings Plc ("Scancell" or the "Company") Notice of AGM Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, will host its Annual General Meeting on Tuesday 10 October 2017. The AGM details are as follows: ...

Weak mining and consumer stocks hit FTSE

Mining stocks were the main casualties this morning as BHP Billiton (BLT), Fresnillo (FRES) and Anglo American (AAL) ...

All News

11-10-17Result of AGMRNS
10-10-17Directorate ChangeRNS
14-09-17Notice of AGMRNS
13-09-17Weak mining and consumer stocks hit FTSEStockMarketWire
13-09-17Scancell reports good progress in development of Modi-1StockMarketWire
13-09-17Final ResultsRNS
11-09-17Presents Moditope Data at Immunotherapy ConferenceRNS
29-08-17Oncimmune and Scancell Present Autoantibodies DataRNS
11-07-17Scancell notes continued progress on SCIB1StockMarketWire
11-07-17Continued Progress on SCIB1RNS
26-06-17Scancell notes ImmunoBody patent granted in EuropeStockMarketWire
26-06-17DNA ImmunoBody Patent Granted in EuropeRNS
22-05-17Holding(s) in CompanyRNS
19-05-17Holding(s) in CompanyRNS
19-05-17Holding(s) in CompanyRNS
11-05-17Results of PlacingRNS
11-05-17Scancell proposes raising up to £5.0mStockMarketWire
11-05-17Proposed Placing to Raise up to ?5.0 millionRNS
13-04-17Scancell changes registered officeStockMarketWire
13-04-17Change of Registered OfficeRNS
20-03-17Immuno-Oncology Summit Europe 2017RNS
13-03-17Scancell eyes fundraising for Phase II SCIB1 trialStockMarketWire
13-03-17Hardman Research: SCIB development updateRNS
01-03-17Holding(s) in CompanyRNS
31-01-17Scancell widens H1 pretax lossStockMarketWire
31-01-17Interim ResultsRNS
30-01-17Scancell in partnership to advance lung cancer clinical trialsStockMarketWire
30-01-17Partnership to Advance Lung Cancer Clinical TrialsRNS
03-01-17Research Update - AmendmentRNS
03-01-17Scancell Holdings issues research updateStockMarketWire
03-01-17Research UpdateRNS
14-11-16World Immunotherapy Congress and Biotech and MoneyRNS
18-10-16Results of AGMRNS
10-10-16Preparing SCIB2 for clinical study in lung cancerRNS
26-09-16Hardman Report: New frontiers in T-cell activationRNS
23-09-16Notice of AGM - AmendmentRNS
23-09-16Scancell Holdings schedules AGMStockMarketWire
23-09-16Notice of AGMRNS
16-09-16Scancell widens H1 pretax loss StockMarketWire
16-09-16Final ResultsRNS

RSS feeds

  • Editorial news feed for LSE:SCLP Editorial
  • Regulatory news feed for LSE:SCLP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account